Opus Genetics, Inc. (IRD) earnings date
Mar 19, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 10% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 44 days, typically, give or take 18 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Nov 10, 2026 | before open | 41 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Tue, May 12, 2026 | before open | 42 | 8-K |
| Q4 FY2025 | Tue, Mar 10, 2026 | before open | 69 | 8-K |
| Q3 FY2025 | Wed, Nov 12, 2025 | before open | 43 | 8-K |
| Q2 FY2025 | Wed, Aug 13, 2025 | after close | 44 | 8-K |
| Q1 FY2025 | Thu, May 15, 2025 | before open | 45 | 8-K |
| Q4 FY2024 | Mon, Mar 31, 2025 | before open | 90 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update OPGx-BEST1 Cohort 2 Dosing Complete and Data Expected in Q1 2027 OPGx-LCA5 Registrational Phase 3 Trial Fully Enrolled with Initiation of Dosing Expected in Q4 2026 FDA Clearance of IND for OPGx-RDH12, with Phase 1/2 Trial Dosing Planned for Q4 2026 FDA Approval of Phentolamine Ophthalmic Solution 0.75% for Presbyopia Triggers Milestone Payment Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points and Opportunities for Priority Review Vouchers RESEARCH TR" exhibit |
| Q3 FY2026 | "With U.S. Food & Drug Administration (FDA) alignment on a potential pivotal endpoint and Cohort 2 over-enrolled with 11 participants, we expect to have data in Q1 2027, followed by dosing in a potential pivotal Phase 3 trial anticipated to begin in the second half of 2027." exhibit |
| Q3 FY2026 | "Completed enrollment and dosing of 11 participants in the high-dose Cohort 2, with topline data, including 3-month data from Cohort 2 and 6-month data for the three Cohort 1 participants with Best vitelliform macular dystrophy, expected in Q1 2027." exhibit |
| Q3 FY2026 | "The registrational Phase 3 trial is fully enrolled with 8 participants, and initiation of dosing is expected in Q4 2026." exhibit |
| Q3 FY2026 | "Received FDA clearance of the Investigational New Drug (IND) application for OPGx-RDH12 for RDH12-associated Leber congenital amaurosis (RDH12-LCA), with initiation of dosing in a Phase 1/2 trial expected in Q4 2026." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update OPGx-BEST1 Cohort 1 Topline Data Expected in Second Week of September 2026 Enrollment Completed in LCA5 Registrational Trial with Dosing Planned for Q4 2026 RDH12, MERTK and RHO Programs Advancing with Upcoming Initiation of Clinical Testing Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points and Opportunities for Priority Review Vouchers RESEARCH TRIANGLE PARK, N.C. – August 6, 2026 - Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”" exhibit |
| Q2 FY2026 | "“With a focus on execution, we are rapidly advancing five gene therapy programs that address significant unmet need in inherited retinal diseases, with OPGx-BEST1 Cohort 1 clinical data targeted for the second week of September and four additional clinical readouts expected in 2027,” said George Magrath, M.D., Chief Executive Officer of Opus Genetics." exhibit |
| Q2 FY2026 | "Enrollment was completed in Cohort 1 of the Phase 1/2 trial (BIRD-1), with 3-month topline data from Cohort 1 expected during the second week of September 2026, assuming all participants complete their assessments as scheduled." exhibit |
| Q2 FY2026 | "Enrollment in the trial was completed, with dosing of OPGx-LCA5 expected to begin in the fourth quarter of 2026 using clinical drug supply manufactured with the intended commercial processes." exhibit |
| Q2 FY2026 | "Topline data from the study is expected by the end of 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/IRD
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/IRD
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/IRD/"><img src="https://veritasdata.dev/embed/IRD.svg" alt="IRD earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/IRD/)
Script
<script async src="https://veritasdata.dev/embed/IRD.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/IRD"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.